# G2P tables

=======================================================
====================================================================================================================================================================
Gene symbol DSC2  
=======================================================
====================================================================================================================================================================
Gene mim 125645  
Indication ARVC  
Referral indication Arrhythmogenic right ventricular cardiomyopathy
(ARVC)  
Disease grouping Familial isolated arrhythmogenic cardiomyopathy  
Disease name DSC2-related Arrhythmogenic right ventricular
cardiomyopathy  
Gene disease validity (ClinGen) definitive  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers Typified by incomplete penetrance  
Disease-associated variant consequence altered gene product
sequence;decreased gene product level  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
splice\_region\_variant;splice\_acceptor\_variant;splice\_donor\_variant;frameshift\_variant;stop\_gained;missense\_variant;inframe\_deletion;inframe\_insertion;NMD\_triggering
pmids
17963498;33831308;24070718;17186466;19863551;24793512;20031616;21636032;23911551;17033975;34400560;31028357;23863954;31402444;26310507  
Disease accession MONDO:0012506  
Curated date 25.11.2021  
Expert panel review date 05.01.2022  
Expert panel Cardiomyopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols DSC3  
hgnc id 3036  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
====================================================================================================================================================================

===============================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
===============================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# DSC2-related ARVC is due to decreased gene product level or altered gene product sequence due to a variety of mechanisms (e.g.Â null alleles, trafficking defects, impaired proteolytic processing, absence of or impaired protein-protein interactions) (PMID: 31028357; 23911551; NBK1131). Loss of function is the likely disease mechanism. ClinGen found there was some evidence to support haploinsufficiency as a mechanism. <https://search.clinicalgenome.org/kb/gene-dosage/HGNC:3036>. Autosomal dominant inheritance with incomplete penetrance is the most common mode of transmission (PMID: 21636032; 33831308). Homozygous and compound heterozygous variants have also been described in association with ARVC with or without cutaneous features (PMID: 26310507; 23863954; 24793512; 24070718; 34400560). In some cases, these appear to reflect autosomal recessive inheritance (PMID 24793512; 23863954, 33831308). Instances of digenic inheritance have been identified with DSC2 variants along with other desmosomal gene pathogenic variants (PMID: 24070718). A number of DSC2 variants have been reported in the literature including nonsense, frameshift, splice, missense and inframe insertions and deletions (NBK1131; 17033975; 17963498; 17186466; 20031616; 19863551; 31402444). DSC2-related ARVC appears to be characterised by an increased risk of biventricular involvement and heart failure when compared to PKP2-related ARVC (PMID: 34400560).

=======================================================
====================================================================================================================================================================
Gene symbol DSC2  
=======================================================
====================================================================================================================================================================
Gene mim 125645  
Indication ARVC  
Referral indication Arrhythmogenic right ventricular cardiomyopathy
(ARVC)  
Disease grouping Familial isolated arrhythmogenic cardiomyopathy  
Disease name DSC2-related Arrhythmogenic right ventricular
cardiomyopathy  
Gene disease validity (ClinGen) definitive  
Allelic requirement biallelic\_autosomal  
Inheritance Autosomal recessive  
Inheritance modifiers Typified by incomplete penetrance  
Disease-associated variant consequence altered gene product
sequence;decreased gene product level  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
splice\_region\_variant;splice\_acceptor\_variant;splice\_donor\_variant;frameshift\_variant;stop\_gained;missense\_variant;inframe\_deletion;inframe\_insertion;NMD\_triggering
pmids
17963498;33831308;24070718;17186466;19863551;24793512;20031616;21636032;23911551;17033975;34400560;31028357;23863954;31402444;26310507  
Disease accession MONDO:0012506  
Curated date 25.11.2021  
Expert panel review date 05.01.2022  
Expert panel Cardiomyopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols DSC3  
hgnc id 3036  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
====================================================================================================================================================================

===============================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
===============================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# DSC2-related ARVC is due to decreased gene product level or altered gene product sequence due to a variety of mechanisms (e.g.Â null alleles, trafficking defects, impaired proteolytic processing, absence of or impaired protein-protein interactions) (PMID: 31028357; 23911551; NBK1131). Loss of function is the likely disease mechanism. ClinGen found there was some evidence to support haploinsufficiency as a mechanism. <https://search.clinicalgenome.org/kb/gene-dosage/HGNC:3036>. Autosomal dominant inheritance with incomplete penetrance is the most common mode of transmission (PMID: 21636032; 33831308). Homozygous and compound heterozygous variants have also been described in association with ARVC with or without cutaneous features (PMID: 26310507; 23863954; 24793512; 24070718; 34400560). In some cases, these appear to reflect autosomal recessive inheritance (PMID 24793512; 23863954, 33831308). Instances of digenic inheritance have been identified with DSC2 variants along with other desmosomal gene pathogenic variants (PMID: 24070718). A number of DSC2 variants have been reported in the literature including nonsense, frameshift, splice, missense and inframe insertions and deletions (NBK1131; 17033975; 17963498; 17186466; 20031616; 19863551; 31402444). DSC2-related ARVC appears to be characterised by an increased risk of biventricular involvement and heart failure when compared to PKP2-related ARVC (PMID: 34400560).

=======================================================
====================================================================================================================================
Gene symbol JUP  
=======================================================
====================================================================================================================================
Gene mim 173325  
Indication ARVC  
Referral indication Arrhythmogenic right ventricular cardiomyopathy
(ARVC)  
Disease grouping Rare familial disorder with ARVC  
Disease name JUP-related Naxos disease  
Gene disease validity (ClinGen) strong  
Allelic requirement biallelic\_autosomal  
Inheritance Autosomal recessive  
Inheritance modifiers NA  
Disease-associated variant consequence altered gene product sequence  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
missense\_variant;inframe\_deletion;frameshift\_variant\_NMD\_escaping  
pmids
25820315;21320868;25705887;17924338;10902626;11691526;20031617;21673311;32966140;8858175;20130592;28098346;15851108;8954745;31402444
Disease accession MONDO:0011017  
Curated date 12.12.2021  
Expert panel review date 05.01.2022  
Expert panel Cardiomyopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols CTNNG  
hgnc id 6207  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
====================================================================================================================================

============================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
============================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# JUP-related Naxos disease (ARVC, woolly hair and palmoplantar keratoderma) is due to altered gene product sequence causing loss of function of JUP (PMID: 25705887; 21673311; 11691526; 10902626). JUP encodes the protein plakoglobin. Kaplan et al found that in 4 Naxos patients, Connexin43 expression at intercellular junctions was significantly reduced and mutant plakoglobin was expressed but failed to localize normally at intercellular junctions (<PMID:15851108>). Inheritance is autosomal recessive. The initial nine patients described ranged in age from 7 to 41 years. Since then, more patients have been discovered carrying the disease with an estimate of 1:1000 in the population of the Greek islands. The disease has also been diagnosed in other countries (PMID: 32966140). A homozygous 2bp deletion in plakoglobin (JUP), c.2157delTG, causing a frameshift and premature termination of the protein and expression of a truncated plakoglobin lacking 56 residues from the C terminus was described in 2000 (<PMID:10902626>). The truncated protein was identified on western blot. In 2017, a homozygous missense variant was described in 7 unrelated French-Canadian individuals. All had typical hair and skin findings; 4/7 had ARVC presenting after 28 years (PMID: 28098346). The effect of this variant in the heterozygous state was not investigated. Two siblings of consanguineous parents were found to have a homozygous 3bp deletion in JUP c.901903delGAG (p.Glu301del). Both had woolly hair and skin findings, only the older sister had ARVC and neither had palmoplantar keratoderma (PMID: 28098346). In OMIM there have been reports of other types of homozygous variants (nonsense, splice, missense) in JUP causing overlapping phenotypes and segregating with disease. Data on biallelic LoF variants are sparse. In mice, generation of a null mutation of the plakoglobin gene by homologous recombination results in embryonic lethality (PMID: 8954745; 8858175). There are 2 reports in humans who had skin features but no obvious cardiomyopathy (PMID: 20130592; 21320868). In one, JUP expression in the skin was absent. Cardiac JUP expression was not directly measured to establish the consequence in the heart therefore it is not known whether variant allele was expressed, degraded, or rescued by alternate splicing. To note dominant pathogenic variants in JUP have also been rarely described in association with ARVC. Asimaki et al reported a dominant variant in JUP in a German family with ARVC and no obvious cutaneous abnormalities (PMID: 17924338). Other studies have identified heterozygous missense variants however their pathogenicity is still debated (PMID 25820315; 20031617; 31402444).

=======================================================
===================================================================================================================================================================================
Gene symbol SCN5A  
=======================================================
===================================================================================================================================================================================
Gene mim 600163  
Indication BrS  
Referral indication Brugada Syndrome (BrS)  
Disease grouping Brugada Syndrome  
Disease name SCN5A-related Brugada syndrome  
Gene disease validity (ClinGen) definitive  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers Typified by incomplete penetrance  
Disease-associated variant consequence altered gene product
sequence;decreased gene product level  
mechanism NA  
mutation consequence flag restricted repertoire of mutations  
Restricted repertoire of pathogenic variants Intronic variants with
functional evidence: NM\_000335.5(SCN5A):c.3228+551T&gt;G (p.?)  
Variant classes reported with evidence of pathogenicity
splice\_region\_variant;splice\_acceptor\_variant;splice\_donor\_variant;missense\_variant;inframe\_deletion;inframe\_insertion;stop\_gained\_NMD\_triggering;frameshift\_variant\_NMD\_triggering
pmids
32850980;9521325;20564468;32533946;20031634;17075016;17442746;25905440;11748104;20129283;29959160;33164571;33131149;25829473;30203441;32893267;29798782;39391988  
Disease accession MONDO:0011001  
Curated date 29.01.2021  
Expert panel review date 21.07.2021  
Expert panel Channelopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols CMD1E  
hgnc id 10593  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
===================================================================================================================================================================================

=========================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
=========================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# SCN5A-related Brugada syndrome is caused by decreased gene product level or altered gene product sequence due to a variety of mechanisms (e.g.Â decreased expression of cardiac sodium channel, Nav1.5 in the sarcolemma, expression of non-functional channels, or altered gating properties leading to a decreased INa sodium current (e.g., delayed activation or earlier or faster inactivation)) (PMID: 29798782). The disease mechanism is loss of function. To date, SCN5A is the only gene classified as having definitive evidence as a cause of monogenic Brugada syndrome (BrS) by ClinGen (PMID: 29959160). SCN5A pathogenic variants are identified in approx. 20- 30% of cases of European ancestry (PMID: 30139433; PMID 33164571). This contribution may differ in other populations. SCN5A-related Brugada syndrome is characterized by autosomal dominant inheritance with incomplete penetrance (PMID 9521325; 11748104; 25905440; 20031634; 33164571; NBK1517). Hundreds of variants, both truncating and non-truncating, have been described in association with Brugada syndrome. Kapplinger et al 2010 (PMID: 20129283) identified 293 distinct variants in SCN5A: 193 missense, 32 nonsense, 38 frameshift, 21 splice-site, and 9 inframe deletions/insertions. Walsh et al 2020 (PMID: 32893267) found that non truncating variants were highly enriched in European cases in the SCN5A transmembrane regions. More recently, a rare non-coding variant in an SCN5A intronic enhancer region has been identified in 9 patients with Brugada syndrome in Thailand (3.9% of the patient cohort). The variant is highly enriched compared to population matched controls and has been functionally validated. It causes significantly reduced SCN5A expression and a reduction in Nav1.5-mediated sodium current density. Authors describe a severe phenotype associated with this variant, 8/9 (89%) of the patients had experienced a cardiac arrest. The variant is in the RE5 enhancer region, 3-38580380-A-C (GRCh38) (PMID: 39391988). Gain of function variants are associated with Long QT syndrome. Although loss of function appears to be the accepted mechanism in Brugada syndrome the SCN5A genotype/phenotype association is still not completely understood. Uncommonly, a single variant can cause both loss of peak current and gain of late current and can lead to a mixed phenotype of LQTS and BrS (PMID: 29806494).

=======================================================
===================================================== Gene symbol
TNNT2  
=======================================================
===================================================== Gene mim 191045  
Indication DCM  
Referral indication Dilated Cardiomyopathy (DCM)  
Disease grouping Familial dilated cardiomyopathy  
Disease name TNNT2-related Dilated cardiomyopathy  
Gene disease validity (ClinGen) definitive  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers NA  
Disease-associated variant consequence altered gene product sequence  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
missense\_variant  
pmids 11106718;29367541;27532257;15542288;20978592;20031601 Disease
accession MONDO:0007267  
Curated date 31.03.2021  
Expert panel review date 08.12.2021  
Expert panel Cardiomyopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols CMD1D;CMH2  
hgnc id 11949  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
=====================================================

=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# Pathogenic variants in TNNT2 cause DCM due to altered gene product sequence. Only missense variants have confidently been reported as pathogenic in TNNT2 DCM cases. There are no reports of truncating variants and TNNT2 has a ClinGen Dosage haploinsufficiency score of 0, and a PLi of 0 in gnomAD (19.6 expected and 20 observed). TNNT2-related DCM is inherited in an autosomal dominant manner, and disease is often an aggressive arrhythmogenic phenotype with high rates of heart failure and sudden cardiac death. TNNT2 missense mutations account for 3% of genetic DCM (<PMID:27532257>). TNNT2 variants are associated with an early-onset and more severe form of DCM. Of note pathogenic variants in TNNT2 are also associated hypertrophic and restrictive cardiomyopathies.

=======================================================
========================================================================================================================================================================================================================================================================================================
Gene symbol TTN  
=======================================================
========================================================================================================================================================================================================================================================================================================
Gene mim 188840  
Indication DCM  
Referral indication Dilated Cardiomyopathy (DCM)  
Disease grouping Familial dilated cardiomyopathy  
Disease name TTN-related Dilated cardiomyopathy  
Gene disease validity (ClinGen) definitive  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers Typified by incomplete penetrance; Typified by
age-related onset  
Disease-associated variant consequence altered gene product
sequence;decreased gene product level  
mechanism NA  
mutation consequence flag restricted repertoire of mutations  
Restricted repertoire of pathogenic variants Variants must occur in
A-band or &gt;90% percentage spliced in (PSI) exons. Pathogenic missense
variants are very rare. Missense variants with segregation evidence:
NM\_001267550.2(TTN):c.2926T&gt;C (p.Trp976Arg);
NM\_001267550.2(TTN):c.533C&gt;A (p.Ala178Asp);
NM\_001267550.2(TTN):c.11674T&gt;A (p.Cys3892Ser) Variant classes
reported with evidence of pathogenicity
splice\_acceptor\_variant;splice\_donor\_variant;frameshift\_variant;stop\_gained;missense\_variant;stop\_gained\_NMD\_triggering;frameshift\_variant\_NMD\_triggering;exon\_loss\_variant  
pmids
23418287;9826585;9817758;25759365;19789381;25589632;32160020;31849696;18765796;28045975;27625337;11788824;37253077;29316444;27869827;29238064;26084686;32013205;26315439;22335739  
Disease accession MONDO:0011400  
Curated date 31.03.2021  
Expert panel review date 08.12.2021  
Expert panel Cardiomyopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols CMD1G  
hgnc id 12403  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
========================================================================================================================================================================================================================================================================================================

=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
=====================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# Pathogenic variants in TTN cause an estimated 15-20% of familial DCM due to decreased gene product level and altered gene product sequence. The likely disease mechanism is loss of function however, it is unclear whether this is due to haploinsufficiency or a dominant negative effect, and it is likely that both mechanisms contribute. It is likely that the reduced function has a direct effect on the sarcomere, leading to impaired contractility. Truncating variants, specifically in exons constitutively expressed in cardiac tissue (percentage spliced in (PSI) &gt;90%) see (PMID: 25589632; 27869827; 32160020), are responsible for the vast majority of TTN-related DCM cases. Missense variants are difficult to interpret, and generally not classified as disease-causing, although there are reports of at least three missense variants with evidence of pathogenicity.TTN missense variants with segregation evidence: p.Trp976Arg (PMID: 11788824) p.Ala178Asp (PMID: 27625337) p.Cys3575Ser (<https://www.biorxiv.org/content/10.1101/2020.09.05.282913v1.full.pdf>) - note not yet peer reviewed. TTN-related DCM is inherited as an autosomal dominant trait and displays incomplete and age-related onset. TTN truncating variants are present in ~1% of the general population, although these variants are more likely to reside in isoforms with lower functional expression in cardiac tissue.

=======================================================
================================================================================
Gene symbol ACTC1  
=======================================================
================================================================================
Gene mim 102540  
Indication HCM  
Referral indication Hypertrophic Cardiomyopathy (HCM)  
Disease grouping Familial hypertrophic cardiomyopathy  
Disease name ACTC1-related Hypertrophic cardiomyopathy  
Gene disease validity (ClinGen) definitive  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers NA  
Disease-associated variant consequence altered gene product sequence  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
missense\_variant;inframe\_deletion  
pmids
10966831;20031618;17611253;28972856;27532257;26061005;10330430;28007147;23604709
Disease accession MONDO:0012799  
Curated date 10.10.2021  
Expert panel review date 10.11.2021  
Expert panel Cardiomyopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols ACTC  
hgnc id 143  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
================================================================================

======================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
======================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# ACTC1 pathogenic variants cause HCM through altered gene product sequence. The disease mechanism is not definitively known but may involve impact on sarcomere force generation. There is currently little evidence to support haploinsufficiency as a mechanism. Inheritance is autosomal dominant. There is limited information regarding penetrance. The initial missense variant identified by Mogensen et al was reported to be highly penetrant in family members but with a variable age of onset and severity (<PMID:10330430>). ACTC1 variants account for &lt;3-5% of HCM cases (NBK1768; PMID: 20031618). Heterozygous missense variants are the major type of pathogenic variants found. One inframe deletion (a deletion of a single amino acid, Phe92del) has been reported in association with HCM (PMID: 20031618). This variant is classified as likely pathogenic on ClinVar. Liu et al suggest it may act to change the local structure and arrangement of amino acids in the actomyosin binding site (PMID: 28972856). Large deletions or duplications have not been described.

=======================================================
=========================================================================================================================================================
Gene symbol ACTN2  
=======================================================
=========================================================================================================================================================
Gene mim 102573  
Indication HCM  
Referral indication Hypertrophic Cardiomyopathy (HCM)  
Disease grouping Familial hypertrophic cardiomyopathy  
Disease name ACTN2-related cardiac and skeletal myopathy  
Gene disease validity (ClinGen) definitive  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers NA  
Disease-associated variant consequence altered gene product
sequence;decreased gene product level  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
frameshift\_variant\_NMD\_triggering;stop\_gained\_NMD\_triggering;missense\_variant;inframe\_deletion;deletion  
pmids
34802252;34526680;20022194;25224718;25173926;30630173;31956495;31680489;17097056;27532257;31983221;33500567;32973354;30701273;30900782;38311799;
39971408 Disease accession MONDO:0000591  
Curated date 10.10.2024  
Expert panel review date 17.03.2025  
Expert panel ClinGen HCVD GCEP  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols NA  
hgnc id 164  
g2p gene disease pair entry date NA  
=======================================================
=========================================================================================================================================================

==============================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
==============================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# Pathogenic variants in ACTN2 are definitively associated with cardiac and skeletal myopathy. They can cause disease through decreased gene product level and altered gene product sequence. ClinGen originally curated ACTN2 for intrinsic cardiomyopathy (hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM)) but this was re-evaluated and expanded to include other cardiomyopathy types and skeletal muscle phenotypes in December 2024 (PMID 39971408). ClinGen found no difference in the mechanisms underlying these different disease entities and therefore have grouped them together. Individuals can show variable cardiomyopathy phenotypes, arrhythmias and sudden death (PMID: 34526680); the phenotype can vary between individuals in the same family. Pathogenic variants in this gene can give rise to isolated left ventricular hypertrophy (LVH). The inheritance pattern is autosomal dominant; however there has been a report of a homozygous ACTN2-truncating variant (in the terminal exon) with a recessive mode of inheritance leading to restrictive cardiomyopathy (RCM) (PMID: 34802252). The skeletal phenotype is also variable and includes distal myopathy and congenital myopathy. As per ClinGen âThe skeletal muscle cases reported in different families carrying ACTN2 variants had homozygous and heterozygous missense variants reported. In the combined cases, where patients presented with both cardiac and skeletal muscle phenotypes, the proband showed frameshift and missense ACTN2 variantsâ (PMID: 30701273, PMID: 30900782, PMID: 38311799). Missense, nonsense, frameshift and larger deletions have all been reported in association with cardiomyopathy phenotypes. 4 missense variants have segregation data and 3 have functional data to support pathogenicity. Patients with these variants presented with atypical and diverse phenotypes. In their review, Walsh et al summarise what is known about ACTN2 variants and their role in cardiomyopathy (PMID: 34526680). Missense variants with segregation evidence: NM\_001103.4(ACTN2): c.355G&gt;A (p.Ala119Thr) PMID: 20022194, <PMID:25224718>; NM\_001103.4(ACTN2): c.683T&gt;C (p.Met228Thr) PMID: 25173926; NM\_001103.4(ACTN2): c.959T&gt;G (p.Leu320Arg) PMID: 30630173; NM\_001103.4(ACTN2): c.1418A&gt;G (p.Tyr473Cys) PMID: 31956495. Missense variants with functional evidence: NM\_001103.4(ACTN2): c.740C&gt;T (p.Thr247Met) PMID: 31680489; NM\_001103.4(ACTN2):c.332G&gt;T (p.Gly111Val) PMID: 17097056; NM\_001103.4(ACTN2):c.355G&gt;A (p.Ala119Thr) PMID: 20022194. According to Genome Aggregation Database (gnomAD), loss of function variants are constrained in ACTN2. There have been reports of deletions in ACTN2 leading to disease. An exon 3-6 deletion leading to a frameshift was found in two families with left ventricular non compaction (LVNC) and HCM (PMID 32973354) and an exon 8-10 deletion leading to an in frame deletion was found in a family with LVNC and arrhythmias (PMID: 34802252, PMID: 34526680). Truncating variants in ACTN2 have been identified in approximately 1% of patients previously classified as having LVNC. These variants were significantly enriched in individuals with an LVNC classification compared to controls (0.65% vs.Â 0.01%, p = 1.3E-06) (PMID 33500567). Of note, it is unclear whether these âLVNCâ individuals exhibited both hypertrabeculation and cardiomyopathy or only hypertrabeculation. Overall, rare variants are not enriched for ACTN2 in HCM or DCM cohorts which suggests they are rarely causative of disease so should be interpreted with caution in cardiomyopathy patients (PMID: 27532257, PMID: 31983221). Expert review panel: ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel. Review date: 17/03/2025

=======================================================
================================= Gene symbol CACNA1C  
=======================================================
================================= Gene mim 114205  
Indication LQTS  
Referral indication Long QT Syndrome (LQTS)  
Disease grouping Familial Long QT Syndrome  
Disease name CACNA1C-related Long QT syndrome Gene disease validity
(ClinGen) moderate  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers NA  
Disease-associated variant consequence NA  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity NA  
pmids NA  
Disease accession NA  
Curated date NA  
Expert panel review date NA  
Expert panel NA  
organ specificity list Heart/Cardiovasculature/Lymphatic panel Cardiac  
prev symbols NA  
hgnc id NA  
g2p gene disease pair entry date NA  
=======================================================
=================================

=======================================================================================================================================================================================
Narrative  
=======================================================================================================================================================================================
<br />

# The gene disease validity assertion is âmoderateâ from ClinGen. No inheritance or mechanism curations have been done in the absence of an established gene disease relationship.

=======================================================
============================================== Gene symbol CALM1  
=======================================================
============================================== Gene mim 114180  
Indication LQTS  
Referral indication Long QT Syndrome (LQTS)  
Disease grouping Long QT syndrome with an atypical presentation Disease
name CALM1-related Long QT syndrome  
Gene disease validity (ClinGen) definitive  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers Typically de novo  
Disease-associated variant consequence altered gene product sequence  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
missense\_variant  
pmids 31170290;31983240;23388215;26969752  
Disease accession MONDO:0014548  
Curated date 14.10.2020  
Expert panel review date 16.06.2021  
Expert panel Channelopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols CALML2  
hgnc id 1442  
g2p gene disease pair entry date 2022-04-26T11:53:00Z  
=======================================================
==============================================

==========================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
==========================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# CALM1-related LQTS is caused by an altered gene product sequence. Reduction in the calcium dependent inactivation of the calcium channel CaV1.2 results in increased inward calcium channel current (ICaL) and repolarization delay. The disease mechanism is likely a dominant negative effect. The three CALM genes encode an identical 149aa protein, calmodulin. The CALM1 gene is located on chromosome 14, CALM2 on chromosome 2 and CALM3 on chromosome 19. Calmodulin protein is involved in many calcium-dependent intracellular processes. All three CALM genes have been classified as Definitive for LQTS and Moderate for CPVT, certain variants are only associated with one or other phenotype, whereas others are associated with a mixed or variable phenotypes. All variants with evidence of pathogenicity identified in the CALM genes are missense: at least 35 distinct missense variants have been identified and reported in the International Calmodulinopathy Registry including 11 (31%) in CALM1, 16 (46%) in CALM2, and 8 (23%) in CALM3. The majority of variants across the CALM genes affect amino acid residues in the EF-hand Ca2+ binding loop III and IV. Some variants have additional evidence in that the same substitution has been seen in paralogous CALM genes, or that the same substitution has been seen in a related phenotype (LQTS). Most variants are unique, but 9 were present in more than one index case and among these, three (p.Asn98Ser, p.Asp130Gly, and p.Phe142Leu, identified in 10, 5, and 4 families, respectively.) appear to be recurrent. While variants p.Asp130Gly and p.Phe142Leu have always been reported as associated with the LQTS phenotype, the variant p.Asn98Ser has phenotypic variability, including LQTS, CPVT, idiopathic VF and sudden death. The majority of CALM variants are de novo. Pathogenic variants in the CALM genes have been associated with: presentation in infancy or early childhood (up to 5 years); marked sinus bradycardia or atrioventricular block and QT prolongation; and, predominantly with CALM1 variants, a mild-to-severe neurological impairment, including seizures, development delay, motor and/or cognitive disability. The phenotype most frequently shown by patients with CALM variants is LQTS, but some patients display other phenotypes including CPVT, idiopathic VF and sudden unexplained death. Some variants have been associated with both LQTS and CPVT, however Crotti et al (PMID: 31170290) report that âdespite the relatively small numbers of cases, a significant association (p=0.001) was observed between location of mutation and phenotype (Supplementary material online, Figure S1). Indeed, a pathogenic variant in EF-hand IV Ca2+ binding loop was found in the majority (17/32, 53%) of CALM-LQTS index cases but in only one of the nine CALM-CPVTs (11%). Conversely, variants identified in CALM-CPVT index cases were mostly located either in EF-hand III (n=5, 56%), or in the inter-EF hand I-II linker (n=3, 33%).â

=======================================================
=========================================================================================================================================================================================================
Gene symbol KCNQ1  
=======================================================
=========================================================================================================================================================================================================
Gene mim 607542  
Indication LQTS  
Referral indication Long QT Syndrome (LQTS)  
Disease grouping Syndromic QT prolongation and cardiac arrhythmias  
Disease name KCNQ1-related Jervell and Lange-Nielsen syndrome  
Gene disease validity (ClinGen) definitive  
Allelic requirement biallelic\_autosomal  
Inheritance Autosomal recessive  
Inheritance modifiers NA  
Disease-associated variant consequence absent gene product;altered gene
product sequence  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
splice\_acceptor\_variant;splice\_donor\_variant;frameshift\_variant;stop\_gained;missense\_variant;stop\_gained\_NMD\_triggering;frameshift\_variant\_NMD\_triggering;exon\_loss\_variant;complex\_structural\_alteration
pmids
27041150;23591039;9020846;27868350;23392653;31983240;11226272;25187895  
Disease accession MONDO:0024540  
Curated date 01.05.2021  
Expert panel review date 16.06.2021  
Expert panel Channelopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols LQT;KCNA9  
hgnc id 6294  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
=========================================================================================================================================================================================================

===========================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
===========================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# Biallelic pathogenic variants in KCNQ1 cause JLNS due to absent gene product level or altered gene product sequence. Both homozygous and compound heterozygous pathogenic variants in KCNQ1 have been reported in JLNS. Nonsense, frameshift, splice site, whole exon deletions and missense variants have been reported as pathogenic. Bhuiyan and Wilde (PMID: 23591039) compared two groups of patients with homozygous variants in KCNQ1. Those patients where there was residual IKs (slowly activating delayed rectifier potassium channel/current) even as little as 10%, had QT prolongation but no hearing loss (autosomal recessive LQTS), whereas those patients with complete absence of IKs had both QT prolongation and hearing loss (JLNS). They concluded that homozygous or compound heterozygous nonsense, frameshift or exon skipping variants resulting in 100% loss of IKs would result in JLNS. In addition, biallelic missense mutations that lead to a protein product that does not traffic to the cell membrane (or is subject to nonsense mediated decay) will lead to JLNS. Note: heterozygous variants in KCNQ1 lead to dominant LQTS.

=======================================================
=============================================================================================================================================================================================================================
Gene symbol KCNH2  
=======================================================
=============================================================================================================================================================================================================================
Gene mim 152427  
Indication SQTS  
Referral indication Short QT Syndrome (SQTS)  
Disease grouping Classic SQTS  
Disease name KCNH2-related Short QT syndrome  
Gene disease validity (ClinGen) definitive  
Allelic requirement monoallelic\_autosomal  
Inheritance Autosomal dominant  
Inheritance modifiers NA  
Disease-associated variant consequence altered gene product sequence  
mechanism NA  
mutation consequence flag NA  
Restricted repertoire of pathogenic variants NA  
Variant classes reported with evidence of pathogenicity
missense\_variant  
pmids
29876509;21130771;30582453;30175559;29759541;29016797;9547387;18692916;14676148;25974115;7889573;30947366;30496390;19088443;30571592;7736582;29574456;21310316;15673388;15828882;31049424;28491588;25335996;19340359;31072576
Disease accession MONDO:0012312  
Curated date 21.07.2021  
Expert panel review date 21.07.2021  
Expert panel Channelopathy expert panel  
organ specificity list Heart/Cardiovasculature/Lymphatic  
panel Cardiac  
prev symbols LQT2  
hgnc id 6251  
g2p gene disease pair entry date 2022-04-25T12:45:00Z  
=======================================================
=============================================================================================================================================================================================================================

================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
Narrative  
================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================================
<br />

# SQTS is a rare (&lt; 1/10,000) AD inherited arrhythmia syndrome associated with atrial fibrillation, ventricular arrhythmia, and risk of sudden cardiac arrest. Diagnosis is based on a diagnostic scorecard (PMID: 21310316), similar to LQTS. Approximately 20% of diagnosed cases will have a genetic cause, and KCNH2 is the most common identified gene.It is noteworthy that of the 18 probands with SQTS in whom KCNH2 variants have been identified, 13 had one of 2 variants; 7 with p.Thr618Ile variant (ClinVar Variation ID# 67297) and 6 with p.Asn588Lys (ClinVar Variation ID# 14436; NM\_172056.2). There is high penetrance for these recurrent variants. Experimental evidence derived from non-patient cells, human-induced pluripotent stem cell-derived cells and a rabbit animal model (PMID: 30496390) all support the relationship of this gene with SQTS, with a gain-of-function mechanism. These experimental studies demonstrate that genetic variants identified in SQTS patients lead to potassium current perturbations concordant with SQTS phenotype and shortening of the QT interval. Note loss-of-function variants in KCNH2 are associated with Long QT Syndrome (LQTS).
